Laboratory Corp of America Holdings has been granted a patent for methods and systems utilizing liquid chromatography/tandem mass spectrometry (LC-MS/MS) to detect and quantify the endogenous biomarker PGD2 in biological samples, aiding in clinical diagnoses. The method includes sample preparation and measurement steps. GlobalData’s report on Laboratory Corp of America Holdings gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Laboratory Corp of America Holdings, Molecular diagnosis biomarkers was a key innovation area identified from patents. Laboratory Corp of America Holdings's grant share as of June 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Detection and quantification of pgd2 in biological samples
The granted patent US12025619B2 outlines a method for detecting and quantifying prostaglandin D2 (PGD2) in biological samples using tandem mass spectrometry. The method involves several key steps: obtaining a biological sample, such as urine or serum, and adding a stable isotope-labeled PGD2 as an internal standard. The sample undergoes liquid chromatography, specifically high turbulence liquid chromatography (HTLC), to purify PGD2 before it is analyzed by tandem mass spectrometry. The mass spectrometry process includes generating precursor ions and fragment ions, which are then detected to determine the presence and quantity of PGD2 in the sample. The method allows for the measurement of PGD2 concentrations ranging from 1.0 pg/mL to 1,000 pg/mL.
Additionally, the patent describes various enhancements to the method, such as the option for an additional purification step, which may include solid phase extraction (SPE). The internal standard can be PGD2-d9, and the detection process can utilize electrospray ionization (ESI) in negative ion mode. The patent also includes provisions for creating calibration curves by spiking known amounts of PGD2 into samples, thereby enabling back-calculation of PGD2 levels. Furthermore, a system for implementing this method is described, which includes stations for sample preparation, purification, chromatographic separation, and mass spectrometric analysis. A computer-program product is also detailed, designed to facilitate the execution of the method through machine-readable instructions.
To know more about GlobalData’s detailed insights on Laboratory Corp of America Holdings, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
